Numerous studies have proved that various lncRNAs, such as WASH5P and CKMT2-AS1, have been available to be potential biotherapeutic targets for CRC, thus limiting the progression of CRC [98,99,100]. This evidence concerns the gene CKMT2 and colorectal carcinoma.